Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Theriva Biologics, Inc. (TOVX)

Theriva Biologics sells SYN-004 enzyme portfolio to Biossil for $350,000 upfront

Neutral Impact 3 of 5 m&a Written later

On October 30, 2026, Theriva Biologics sold its SYN-004 (ribaxamase) and related SYN-006 antibiotic-degrading enzyme assets to Biossil Labs Inc., with the closing on the same day. Theriva received a $350,000 upfront payment and is eligible for regulatory and sales milestones and royalties, subject to a $250 million royalty cap, while Biossil takes over development and commercialization. Future payments are not assured, and Theriva must share part of its proceeds with PREV ABR LLC under an amended agreement.

Key points

  • Closing occurred October 30, 2026, and Theriva received a non-refundable $350,000 upfront payment
  • Theriva is eligible for up to $3 million in regulatory milestones, up to $88 million in sales milestones, and low-single-digit royalties capped at $250 million
  • Theriva paid PREV ABR LLC $140,000 at closing and will owe PREV 50% of milestones, 33 1/3% of royalties and 50% of other consideration, subject to a $13.0 million cap

The filing

CompanyTheriva Biologics, Inc. (TOVX)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:05 PM ET
Accession number0001104659-26-121318

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.